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Abstract
PURPOSE: LIM domain only 2 (LMO2) has been identified as a novel oncogene associated with carcinogenesis
and better prognosis in several malignant tumors. We investigate the involvement of LMO2 in pancreatic cancer.
EXPERIMENTAL DESIGN: We evaluated LMO2 expression in cultured cells, bulk tissues, and microdissected cells
from pancreatic cancers by quantitative reverse transcription–polymerase chain reaction and immunohistochemistry.
RESULTS: Of 164 pancreatic cancers, 98 (60%) were positive for LMO2 expression. LMO2 was more frequently de-
tected in high-grade pancreatic intraepithelial neoplasia (PanIN) lesions (PanIN-2 and -3) than in low-grade PanIN le-
sions (PanIN-1A and -1B; P < .001) and was not detected in normal pancreatic ductal epithelium. The LMO2
messenger RNA levels were significantly higher in invasive ductal carcinoma cells than in normal pancreatic cells
as evaluated by quantitative reverse transcription–polymerase chain reaction analyses of microdissected cells (P =
.036). We also found higher incidence of LMO2 expression in histologic grade G1/G2 cancers than in grade G3
cancers (P < .001). The median survival time of LMO2-positive patients was significantly longer than that of
LMO2-negative patients (P < .001), and multivariate analyses revealed that high LMO2 expression was an inde-
pendent predictor of longer survival (risk ratio, 0.432, P < .001). Even among patients with a positive operative mar-
gin, LMO2-positive patients had a significant survival benefit compared with LMO2-negative patients. We further
performed a large cohort study (n = 113) to examine the LMO2 messenger RNA levels in formalin-fixed paraffin-
embedded samples and found similar results. CONCLUSIONS: LMO2 is a promising marker for predicting a better
prognosis in pancreatic cancer.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death
in Western countries and has the lowest patient survival rate of any
solid cancer [1–3]. Recently, although the cancer death rates of most
malignancies have decreased owing to improvements in early detec-
tion and treatment, the overall 5-year survival of patients with pan-
creatic cancer has only slightly increased from 3% to 5% [1] because
of difficulties in the diagnosis of pancreatic cancer at early stages. Sur-
gical resection is the only curative treatment of pancreatic cancer, and
the survival rate for patients with a negative operative margin status
(R0) is significantly higher than that for patients with positive oper-
ative margin status (R1 and R2) [4]. However, some patients with a
positive operative margin survive longer than those with a negative oper-
ative margin, and a more aggressive surgical approach may be justi-
fied for patients with a probability of such a response after resection,
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even if the tumor is large and locally invasive. Conversely, the oper-
ation could be avoided if no surgical benefit can be predicted pre-
operatively. Therefore, we would like to identify a novel marker
for predicting the prognosis of each patient.
The LIM domain only (LMO) proteins comprise one of the LIM
domain-containing protein families and possess only two tandem
LIM domains. These proteins act as adaptors for the assembly of
large multiprotein complexes and play critical roles in both normal
development and oncogenesis [5,6]. There are four members of the
LMO family (LMO1, LMO2, LMO3, and LMO4 ), which have been
recently identified and reported to be oncogenes [7–10]. LMO2 was
also detected in several hematolymphoid neoplasias [11] and cor-
related with a good prognosis in diffuse large B-cell lymphoma
(DLBCL) [12]. Recently, LMO2 was reported to play an important
role in prostate cancer progression, and its expression was associated
with the grade of prostatic intraepithelial neoplasia (PIN), the prema-
lignant lesion of prostate cancer. These data suggest that LMO2 is
associated with carcinogenesis and prognosis in several malignancies.
Similar to PIN, pancreatic intraepithelial neoplasia (PanIN) has
been reported to be a premalignant lesion for conventional pancreatic
cancer [13], and the gradual accumulation of molecular abnormali-
ties supports this progression model. However, the involvement of
LMO2 in pancreatic cancer remains to be investigated. Therefore,
identifying the involvement of LMO2 in pancreatic cancer may be
helpful toward understanding the mechanism of pancreatic carcinogen-
esis and progression and contribute to the detection of a biomarker
for the diagnosis of pancreatic cancer or selection of therapy based
on the features of individual tumors.
In the present study, we analyzed LMO2 expression in a large co-
hort of patients with pancreatic cancer. We focused on its prognostic
and clinicopathological features using immunohistochemical staining
and evaluation of messenger RNA (mRNA) extracted from formalin-
fixed paraffin-embedded (FFPE) samples. We also examined its ex-
pression in PanIN lesions to investigate the involvement of LMO2
in pancreatic carcinogenesis. Our data suggest that LMO2 is associ-
ated with a better prognosis in pancreatic cancer.
Materials and Methods
Clinical Samples
A total of 164 patients with pancreatic ductal adenocarcinomas
underwent surgical resection at the Department of Surgery and On-
cology, Kyushu University Hospital (Fukuoka, Japan) and its affili-
ated hospitals. The patients consisted of 103 men and 61 women
with a median age of 66 years (range, 36-86 years). The median du-
ration of follow-up was 14 months (range, 1-101 months). We also
analyzed 41 patients with unresectable pancreatic cancer due to local in-
vasion or distant metastasis. All tumors were staged according to the
TNM classification system of the International Union against Cancer
[14]. Histologic grading of the tumors and diagnosis of PanIN lesions
were performed according to the World Health Organization’s classifi-
cation system [15]. Other pathological variables (lymphatic invasion,
vascular invasion, and perineural invasion) were based on the Japan
Pancreas Society’s classification [16]. Patients with mucinous cystadeno-
carcinoma or intraductal papillary mucinous carcinoma were excluded
from the study. Surgical specimens were fixed in 10% formalin and
embedded in paraffin. The paraffin-embedded samples were serially
sectioned at 4-μm thickness, mounted on slides, and stained with he-
matoxylin and eosin for histologic analysis. For quantitative reverse
transcription–polymerase chain reaction (qRT-PCR) studies, 22 fresh-
frozen samples were obtained from cancerous lesions of resected pan-
creases from patients with primary pancreatic invasive ductal carcinoma
(IDC) and 7 normal tissue samples were taken from intact pancreatic
tissue resected for bile duct cancer or a pancreatic endocrine tumor. The
tissue samples were embedded in OCT compound (Sakura, Tokyo,
Japan) as soon as possible after resection and stored at −80°C until anal-
ysis. This study was performed in accordance with the principles em-
bodied in the Declaration of Helsinki. The study was also approved by
the Ethics Committee of Kyushu University and conducted according
to the Ethical Guidelines for Human Genome/Gene Research enacted
by the Japanese Government.
Cell Lines and Primary Cultures of Pancreatic Epithelial Cells
Normal human pancreatic epithelial cells were obtained from Cell
Systems (Kirkland, WA) and maintained in CS-C medium contain-
ing 10% fetal calf serum according to the instructions of the supplier.
Eleven pancreatic cancer cell lines, namely, ASPC-1, KP-1N, KP-2,
KP-3, PANC-1, SUIT-2 (provided by Dr. H. Iguchi, National Shikoku
Cancer Center, Matsuyama, Japan), MIA-PaCa2 (Japanese Cancer
Resource Bank, Tokyo, Japan), Capan-1, Capan-2, CFPAC-1, and
SW1990 (American Type Culture Collection, Manassas, VA), were
used. A human pancreatic ductal epithelial cell line (HPDE6-E6E7
clone 6) immortalized by transduction with the E6/E7 genes of human
papillomavirus 16 was kindly provided by Dr. Ming-Sound Tsao (Uni-
versity of Toronto, Toronto, Ontario, Canada). Cells were maintained
as described previously [17,18].
Immunohistochemical Procedures and Evaluation
Sections were cut at 4-μm thickness from paraffin-embedded mate-
rial, deparaffinized in xylene, and rehydrated through a graded ethanol
series. Endogenous peroxidase activity was blocked by incubating with
3% hydrogen peroxide in methanol for 30 minutes. Antigen retrieval
was achieved by microwaving the sections in citrate buffer at pH 6.0.
A Histofine SAB-PO kit (Nichirei, Tokyo, Japan) was used for immu-
nohistochemical labeling. Each section was exposed to 10% nonim-
munized rabbit serum for 10 minutes to block nonspecific binding
of the antibodies, followed by incubation with a goat polyclonal anti-
LMO2 primary antibody (AF2726; R&D Systems, Minneapolis, MN;
1:100 dilution) at 4°C overnight. The sections were then sequentially
incubated with a biotinylated anti–goat immunoglobulin solution for
20 minutes followed by peroxidase-labeled streptavidin for 20 minutes.
The reaction products were visualized using 3,3′-diaminobenzidine as
a chromogen followed by nuclear counterstaining with hematoxylin. In
the present study, cytoplasmic and nuclear immunoreactivities were
detected in the tumor cells. The proportion of LMO2-positive cells
was evaluated using the following scale according to the percentage
of LMO2-positive tumor cells: negative, 0; less than 10%, 1+; 10%
to 50%, 2+; greater than 50%, 3+. The LMO2 expression in tumor
cells was defined as positive when 10% of the tumor cells or greater
were stained (scores 2+ and 3+) and negative when less than 10% of
the tumor cells were stained (scores 0 and 1+). All slides were evaluated
independently by three investigators (K.N., Y.M., and A.H.) without
any knowledge of the clinical features of each case.
RNA Isolation from Microdissected and FFPE Samples
Frozen tissue samples were cut into 5-μm-thick sections. One sec-
tion from each sample was stained with hematoxylin and eosin for
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histologic examination. Invasive ductal carcinoma cells from 11 le-
sions, PanIN-2 cells from 2 lesions, and normal pancreatic ductal
epithelial cells from 5 lesions were isolated selectively using a laser
microdissection and pressure catapulting system (PALM Microlaser
Technologies, Bernried, Germany) in accordance with the manufac-
turer’s protocols. Similar numbers of cells were isolated from sections
of IDC lesions, PanIN lesions, and normal ductal epithelium. More
than 500 cells could be obtained from each IDC section, whereas 3
to 10 sections were needed to isolate sufficient normal ductal epithe-
lial cells and PanIN cells owing to the lower numbers of cells per
section. After the microdissection, total RNA was extracted from
the selected cells and subjected to qRT-PCR for quantification of
LMO2 as described previously [19].
For analysis of FFPE samples, all paraffin blocks were cut into 5-μm-
thick sections. Macrodissection was performed using a safety blade to
enrich the neoplastic cell population, and 3 to 10 sections were used
for RNA extraction. Total RNA was extracted using an RNeasy FFPE
Kit (Qiagen, Tokyo, Japan) with DNase I treatment according to the
manufacturer’s instructions.
Quantitative Assessment of LMO2 mRNA Levels by
One-step qRT-PCR
Total RNA was extracted from bulk tissues using an RNeasy Mini
Kit (Qiagen) and from pellets of cultured cells using a High Pure RNA
Kit (Roche Diagnostics, Mannheim, Germany) with DNase I treat-
ment (Roche Diagnostics) according to the corresponding manufac-
turer’s instructions. We designed specific primers (LMO2: forward,
5′-CACCTGGAATGTTTCAAATGC-3′ and reverse, 5′-TCCTGTTC-
GCACACTATGTCA-3′; 18S rRNA: forward, 5′-GTAACCCGTTGA-
ACCCCATT-3′ and reverse, 5′-CCATCCAATCGGTAGTAGCG-3′)
and performed BLASTsearches to ensure the specificity of each primer.
The extracts were analyzed by qRT-PCR using a QuantiTect SYBR
Green RT-PCR Kit (Qiagen) and a Chrom4 Real-time PCR Detection
System (Bio-Rad Laboratories, Hercules, CA). Each reaction mixture
was first incubated at 50°C for 30 minutes to allow reverse transcrip-
tion, in which first-strand complementary DNA was synthesized by
priming total RNA with the same gene-specific primer (reverse). PCR
was initiated by incubation at 95°C for 15 minutes to activate the
polymerase, followed by 40 cycles of 94°C for 15 seconds, 58°C for
30 seconds, and 72°C for 30 seconds. Each primer set used in the pres-
ent study produced a single prominent band of the expected size after
electrophoresis. Each sample was analyzed twice, and any sample show-
ing more than 10% deviation in the qRT-PCR values was tested a
third time. The level of mRNA expression in each sample was calculated
by reference to a standard curve generated using total RNA from the
PANC-1 human pancreatic cancer cell line. Expression of LMO2
mRNA was normalized by that of 18S rRNA mRNA. Cutoff point se-
lection for the LMO2 mRNA was carried out by searching for a cut
point yielding the smallest log-rank P value and divided to the high
and low levels.
Statistical Analysis
All calculations were carried out using JMP 7.0.1 software (SAS In-
stitute, Cary, NC). Data were analyzed by the Mann-Whitney U test
if comparisons involved two groups because a normal distribution
was not obtained. Survival curves were calculated by the Kaplan-
Meier method, and differences between curves were analyzed by
the log-rank test. The rates of positive LMO2 expression for clinico-
pathological variables were compared using the χ 2 test. We also con-
ducted univariate and multivariate analyses of the prognostic factors
with a survival analysis using the Cox proportional hazards model. All
differences were considered to be statistically significant if P < .05.
Results
LMO2 mRNA Expression Levels in Cultured Pancreatic
Cancer Cells
We investigated the levels of LMO2 mRNA expression in cultures
of 11 different pancreatic cancer cell lines and in cultures of primary
normal pancreatic ductal epithelial cells and HPDE cells. As shown
in Figure 1, all 11 pancreatic cancer cell lines and the HPDE cells
expressed LMO2 mRNA. However, the primary normal pancreatic
ductal epithelial cells did not express LMO2 mRNA.
Quantitative Analyses of LMO2 mRNA Expression Levels in
IDC and Normal Pancreatic Tissues
We measured the LMO2 mRNA levels in 22 IDC bulk tissues and
7 normal pancreatic tissues. The LMO2 mRNA expression levels
were normalized by the 18S rRNA mRNA expression levels as a refer-
ence gene. All the IDC bulk tissues expressed LMO2 mRNA. How-
ever, normal pancreatic tissues expressed no or significantly lower
levels of LMO2 than IDC tissues (Figure 2A; P < .001). There were
no significant associations between the LMO2 mRNA levels and
clinicopathological features such as tumor size, tumor stage, venous
invasion, and differentiation (data not shown). However, the median
LMO2 mRNA level in G1/G2 pancreatic cancer tissues was higher
than that in G3 pancreatic cancer tissues, although the difference did
not reach statistical significance (Figure 2B; P = .072).
Quantitative Analyses of LMO2 mRNA Expression Levels in
Microdissected IDC and Normal Ductal Epithelial Cells
As shown in Figure 2C, the LMO2 mRNA expression levels were
significantly higher in IDC cells than in normal ductal epithelial cells
(P = .036). This trend was consistent with the results of our bulk
tissue analyses. We also analyzed the LMO2 mRNA levels in two
PanIN-1B lesions and found that the mRNA levels were similar to
Figure 1. LMO2mRNA expression levels in 11 pancreatic cancer cell
lines. The expression of LMO2mRNA was normalized by that of 18S
RNA mRNA. Values are expressed relative to 1.00 for expression in
SUIT-2 cells. All 11 pancreatic cancer cells express LMO2 mRNA,
although the expression levels in the MIA-PaCa2 and Capan-2 cell
lines are lower than those in HPDE cells.
714 Overexpression of LMO2 in Pancreatic Cancer Nakata et al. Neoplasia Vol. 11, No. 7, 2009
those in normal ductal epithelial cells. In a case with PanIN-1B and
IDC lesions in the same section, high LMO2 mRNA expression was
detected in the IDC lesions but not in the PanIN-1B lesions (data
not shown).
Immunohistochemical Patterns of LMO2 Expression in IDC
and PanIN Lesions
Immunohistochemical staining for LMO2was performed on pancre-
atic tissues. LMO2 expression was detected in IDC and PanIN lesions.
However, LMO2 expression was not detected in normal pancreatic
ductal epithelium (Figure 3A). LMO2 expression was evaluated in
164 IDC lesions and 30 PanIN lesions. It was detected in different
grades of PanIN and IDC lesions as follows: PanIN-1A, 0% (0/9);
PanIN-1B, 33% (3/9); PanIN-2, 80% (4/5); PanIN-3, 86% (6/7);
IDC, 60% (98/164). LMO2 expression was significantly higher in
high-grade PanIN lesions (PanIN-2 and -3) than in low-grade PanIN
lesions (PanIN-1A and -1B; Table 1; P < .001). LMO2 expression was
negative or very weak in PanIN-1A (Figure 3B) and PanIN-1B
(Figure 3C ) lesions but was moderate to high in PanIN-2 (n = 5;
Figure 3D) and PanIN-3 (n = 7; Figure 3E) lesions. Among 164 cases
of IDC, 98 (60%) were positive for LMO2 expression in the cyto-
plasm and nucleus of the carcinoma cells (Figure 3F). The relation-
ships between LMO2 expression and various clinicopathological
variables are summarized in Table 2. No significant relationships were
found between LMO2 expression and age, sex, lymphatic invasion,
lymph node metastasis, and depth of invasion. However, LMO2 expres-
sion had significant inverse associations with venous invasion (P =
.023) and histologic grade (P < .001). A significantly higher proportion
of tumors with a histologic grade of G1 or G2 (Figure 3G ; 86/120,
72%) was LMO2-positive compared with tumors with a histologic
grade of G3 (Figure 3H ; 12/44, 27%, P < .001; Table 2).
Outcomes after Surgery and Prognostic Factors
We measured the LMO2 mRNA levels in FFPE samples derived
from 113 cases of pancreatic cancer (Figure 4A) and constructed sur-
vival curves based on both immunohistochemical staining and mRNA
expression (Figure 4, B and C ). Among the 164 patients with pancre-
atic cancer, the survival rates of patients with LMO2-positive cancer
were significantly higher than those of patients with LMO2-negative
cancer (Figure 4B; P < .001, log-rank test). Univariate analyses for
overall survival identified LMO2 expression (P < .001), lymph node
metastasis (P < .001), lymphatic invasion (P < .001), venous invasion
(P < .001), and histologic grade (P = .002) as significant prognostic
predictors. Age, sex, and depth of invasion had no prognostic value.
Multivariate analyses of the same set of patients were performed for
LMO2 expression and clinicopathological predictors of survival time.
The results revealed that LMO2 expression was an independent favor-
able prognostic factor (Table 3; risk ratio, 0.432; 95% confidence in-
terval (CI), 0.281-0.665; P < .001).
In accordance with the immunohistochemistry-based curves, the
survival rates of patients with high levels of LMO2 mRNA expression
were significantly higher than those of patients with low levels of
LMO2 mRNA expression (Figure 4C ; P < .001, log-rank test). We
also analyzed LMO2 mRNA normalized by β-actin and showed the
same result (data not shown).
Comparisons between LMO2-Positive and LMO2-Negative
Cases among Positive Operative Margin Cases
Among cases with a positive operative margin, the survival rates
of LMO2-positive patients were significantly higher than those of
LMO2-negative patients (Figure 5A; P < .001, log-rank test). Fur-
thermore, the margin-positive/LMO2-positive group did not show
any significant difference in survival rate compared with the margin-
negative/LMO2-negative group (Figure 5A; P = .250, log-rank test),
and the margin-positive/LMO2-negative group also did not show any
significant difference in survival rate compared with the unresectable
Figure 2. Relative expression levels of LMO2mRNA in bulk tissues
and microdissected cells. Total RNA extracted from frozen bulk
tissues and microdissected cells was subjected to qRT-PCR to
measure the expression of LMO2 mRNA. 18S rRNA was used as
a reference gene. The top and bottom horizontal lines indicate the
75th and 25th percentiles, respectively. The center horizontal lines
represent the sample medians. The vertical lines drawn from the
boxes extend to the 10th and 90th percentiles. (A) Relative LMO2
mRNA expression levels in IDC and normal pancreatic tissues. (B)
Relative LMO2 mRNA expression levels in bulk pancreatic cancer
tissues with G1/G2 and G3 histologic grades. (C) Relative LMO2
mRNA expression levels in microdissected cells.
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Figure 3. Representative microphotographs of LMO2 expression in pancreatic tissues. (A–C) LMO2 expression is not detected in the
normal pancreatic ductal epithelium (A), PanIN-1A (B), and PanIN-1B (C) lesions. (D–F) A moderate to high expression is detected in
PanIN-2 (D), PanIN-3 (E), and IDC (F) lesions. (G, H) LMO2 expression in lesions according to histologic differences. A well-differentiated
adenocarcinoma (G) and a poorly differentiated adenocarcinoma (H) are shown.
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group (Figure 5A; P = .226, log-rank test). These data were consistent
with those of FFPE sample-based mRNA analyses (Figure 5B).
Discussion
This is the first report regarding the involvement of LMO2 in
pancreatic cancer. In the present study, LMO2mRNA expression lev-
els were significantly higher in pancreatic cancer tissues than in nor-
mal tissues or cells in analyses of both bulk tissues and microdissected
cells. These results were supported by findings that pancreatic cancer
cell lines showed high levels of LMO2 mRNA expression, whereas
primary cultures of pancreatic normal epithelial cells did not express
LMO2 mRNA. HPDE cells showed a slight expression of LMO2
mRNA because this cell line is immortalized by the infections of the
retrovirus containing E6 and E7 genes of human papillomavirus 16.
Therefore, its expression profile may be not exactly the same as that
in normal pancreatic ductal cell.
We also performed immunohistochemical studies, and the results
were consistent with those of the mRNA expression analyses. Fur-
thermore, we found that LMO2 expression was significantly associ-
ated with a better prognosis.
Ma et al. [20] demonstrated LMO2 expression in premalignant
lesions in prostate tissues, consistent with our present immunohisto-
chemical and microdissection-based studies. Recently, PanIN-2 was
suggested to be the earliest truly neoplastic lesion in the progression
of pancreatic carcinogenesis, rather than PanIN-1B [21]. The fre-
quency of LMO2 expression in IDC group was lower than that in
high-grade PanIN group, which was possibly due to the low expres-
sion rates of LMO2 in G3 pancreatic tissues. In the present study,
we observed accentuated expression of LMO2 in PanIN-2 lesions.
However, LMO2 expression was also detected in 30% of PanIN-1B
lesions, and it may therefore be difficult to use LMO2 as a clear
marker to distinguish between PanIN-2 and PanIN-1B lesions.
Table 1. LMO2-Positive Ratio According to the Grade of PanIN.
LMO2 Expression P
Positive Negative
Low-grade PanIN* 3 15 <.001
High-grade PanIN† 10 2
*PanIN-1A and PanIN-1B.
†PanIN-2 and PanIN-3.
Table 2. Relation between LMO2 Expression and Clinicopathological Characteristics in Pancre-
atic Cancer.
Variable No. Cases LMO2 Expression Positive
Rate
P
Negative (n = 66) Positive (n = 98)
Age (years)
<59 49 19 30 0.612 .802
>60 115 47 68 0.591
Sex
Male 103 45 58 0.563 .240
Female 61 21 40 0.656
Lymph node metastasis
Negative 52 17 35 0.673 .176
Positive 112 49 63 0.563
Lymphatic invasion
Negative 31 9 22 0.710 .151
Positive 133 57 76 0.571
Venous invasion
Negative 51 14 37 0.725 .023
Positive 113 52 61 0.540
Histologic grading
G1 40 8 32 0.800 <.001
G2 80 26 54 0.675
G3 44 32 12 0.273
Depth of invasion
T1 8 3 5 0.625 .316
T2 9 4 5 0.556
T3 142 55 87 0.613
T4 5 4 1 0.200
Figure 4. LMO2mRNA levels inFFPEsamplesderived from113cases
of pancreatic cancer (A) and Kaplan-Meier survival curves for the pa-
tients. (B, C) Survival curves were created for LMO2-positive, LMO2-
negative, and unresectable patients based on immunohistochemistry
(B) and FFPE sample-based mRNA analyses (C). (B) P < .001, LMO2-
positive patients versus LMO2-negative patients. P < .001, LMO2-
negative patients versus unresectable patients. (C) P < .001, LMO2
mRNA high patients versus LMO2 mRNA low patients. P < .001,
LMO2mRNA low patients versus unresectable patients.
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In our study, multivariate analyses clearly showed that LMO2 ex-
pression was associated with a better prognosis in pancreatic cancer,
consistent with a previous report that LMO2 expression is related with
prolonged survival in DLBCL [12]. Alizadeh et al. [22] reported that
LMO2 was expressed in germinal center B-like DLBCL, a DLBCL
subtype with a better prognosis than DLBCL. They suggested that
LMO2 may play a role in inhibiting the differentiation of the B-cell
lineage and is related with the DLBCL phenotype malignancy. The
present immunohistochemical analyses revealed that LMO2 expres-
sion was significantly correlated with lower histologic grades in pan-
creatic cancer. Conversely, Ma et al. suggested LMO2 expression
was related with aggressive behavior and distant metastasis in prostate
cancer, although its relation with prognosis was not described. There-
fore, the function of LMO2 and its relation with prognosis might be
different in each type of tumor.
In the present study, LMO2 expression was associated with a bet-
ter prognosis in pancreatic cancer and its expression also influenced
the survival rate of patients with a positive operative margin. Surgical
resection is the only curative treatment of managing pancreatic can-
cer, and a negative operative margin was found to be associated with
a greater overall survival compared with a positive operative margin
[4]. Therefore, complete resection (R0) should be considered for
each operation. However, the surgical margins are positive (R1 or
R2) in many cases [23], especially cases with borderline resectable
tumors defined according to the National Comprehensive Cancer
Network. The National Comprehensive Cancer Network also com-
ments that a uniform consensus of resectability has not yet been de-
fined and that approaches to patients with locally invasive cancers
differ among individual institutions. Nevertheless, patients with a
positive operative margin sometimes survive longer than expected.
In our analysis, the survival rate of patients with LMO2 expression
was significantly longer than that of patients without LMO2 expres-
sion, even when the surgical margin was positive. Furthermore, the
survival rates of margin-positive/LMO2-positive patients were as
high as those of margin-negative/LMO2-negative patients. These
findings suggest the possibility that the surgical approach for patients
with borderline resectable tumors could be individualized by the level
of LMO2 expression. Patients with LMO2-negative expression may
not achieve any benefit from surgical resection, and then other treat-
ments, such as chemoradiation, should be given to reduce the oper-
ative morbidity.
We also analyzed LMO2 mRNA levels normalized by both 18S and
β-actin to confirm the immunohistochemistry-based analyses. There
are few reports about pancreatic cancer involving FFPE sample-based
mRNA expression analyses in large cohorts. Formalin-fixed paraffin-
embedded samples are usually associated with large amounts of clinico-
pathological data. Therefore, analyzing FFPE samples may be helpful
for identifying the characteristics of tumors. Moreover, we have already
reported the mRNA expression levels of several genes in pancreatic
juice in studies to identify novel biomarkers for preoperative diagnosis
of pancreatic cancer [24]. Therefore, analyses of LMO2 mRNA levels
in pancreatic cancer may be useful for estimating the operative benefit
in patients with borderline resectable tumors.
In conclusion, we analyzed LMO2 expression in a large cohort of
patients with pancreatic cancer. Our results have revealed that LMO2
is correlated with the prognosis of patients after resection of pancre-
atic cancer.
Table 3. Prognostic Factors in Cox Proportional Hazards Model.
Variable Univariate Multivariate
Risk Ratio 95% CI P Risk Ratio 95% CI P
Age (years)
>60/<59 1.129 0.748-1.749 .572 .435
Sex
Male/female 0.965 0.658-1.432 .859 .648
Depth of invasion
T3, T4/T1, T2 1.470 0.805-3.012 .223 .900
Lymph node metastasis
Positive/negative 1.996 1.316-3.105 .001 .059
Lymphatic invasion
Positive/negative 2.719 1.553-5.228 <.001 .110
Venous invasion
Positive/negative 2.705 1.747-4.340 <.001 1.943 1.174-3.328 .009
Histologic grading*
G3/G1, G2 1.762 1.152-2.643 .010 .123
LMO2
Positive/negative 0.398 0.267-0.596 <.001 0.432 0.281-0.665 <.001
*G1 and G2 were grouped for survival analysis.
Figure 5. Kaplan-Meier survival curves for patients with positive/
negative operative margins with and without LMO2 expression. Sur-
vival curves were created based on immunohistochemistry (A) and
FFPE sample-based mRNA analyses (B). (A) P = .250, margin(+)/
LMO2(+) patients versus margin(−)/LMO2(−) patients. P < .001,
margin(+)/LMO2(+) patients versus margin(+)/LMO2(−) patients.
P = .226, margin(+)/LMO2(−) patients versus unresectable pa-
tients. (B) P = .071, margin(+)/LMO2 mRNA high patients versus
margin(−)/LMO2 mRNA low patients. P = .011, margin(+)/LMO2
mRNA high patients versus margin(+)/LMO2 mRNA low patients.
P = .116, margin(+)/LMO2 mRNA low patients versus unresect-
able patients.
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